EYENOVIA INC. - COMMO

Eyenovia Announces $12 Million Registered Direct Offering

24 Aug 2023 18:47:29 By Nasdaq GlobeNewswire

Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals

16 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update

10 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

09 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10

07 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Eyenovia Announces First Commercial Sale of Mydcombi™

03 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes

26 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023

01 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update

11 May 2023 16:05:01 By Nasdaq GlobeNewswire

Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform

08 May 2023 08:00:00 By Nasdaq GlobeNewswire

Eyenovia to Report First Quarter 2023 Results on Thursday, May 11

04 May 2023 08:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Poster Presentation at ARVO 2023

24 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update

30 Mar 2023 16:05:01 By Nasdaq GlobeNewswire

Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30

23 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement

28 Feb 2023 16:05:01 By Nasdaq GlobeNewswire

Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals

15 Feb 2023 09:51:05 By Nasdaq GlobeNewswire

Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops

12 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Participation at the 2023 International Consumer Electronics Show

20 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

13 Dec 2022 08:00:02 By Nasdaq GlobeNewswire

Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President

08 Dec 2022 08:00:01 By Nasdaq GlobeNewswire